

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

Service Category:

- | | |
|--|--|
| <input type="checkbox"/> Anesthesia | <input type="checkbox"/> Medicine Services and Procedures |
| <input type="checkbox"/> Surgery | <input checked="" type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures | <input type="checkbox"/> DME/Prosthetics or Supplies |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Other: Part B Drugs |

Service Description:

This document addresses the use of Vyalev, a combination of foscarnidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid) approved by the Food and Drug Administration (FDA) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

VYALEV (Foscarnidopa and Foslevodopa) is approved for subcutaneous administration only, preferably in the abdomen, via the VYAFUSER pump.

Background Information:

Parkinson’s disease (PD) is a prevalent neurodegenerative movement disorder that affects millions worldwide. It is characterized by the progressive loss of dopamine-producing neurons in the substantia nigra, leading to a classic symptom triad of tremor, rigidity, and bradykinesia, along with various nonmotor and neuropsychiatric symptoms that impair function and quality of life. PD is not limited to dopamine depletion, as cell loss and biochemical changes occur in multiple brain regions beyond the basal ganglia.

Management of PD involves personalized treatment based on the patient’s symptoms, disease stage, functional status, and activity level. Therapeutic options include pharmacologic, nonpharmacologic, and surgical interventions aimed at optimizing motor function, alleviating nonmotor symptoms, and improving quality of life throughout the disease course.

As PD advances, degeneration of nigrostriatal dopaminergic neurons impairs the storage and conversion of levodopa to dopamine, diminishing the effectiveness of standard levodopa immediate-release formulations. The short half-life of levodopa (approximately 90 minutes) results in fluctuating dopamine levels, narrowing the therapeutic window over time. Factors such as impaired gastric emptying, slow intestinal transit, dietary protein interference, and small intestinal bacterial overgrowth further impact levodopa absorption.

Advanced PD is associated with complications like motor fluctuations and dyskinesia, where patients transition between "on" states (well-controlled symptoms) and "off" states (reappearance of symptoms like tremor and stiffness). Dyskinesia, involving involuntary movements, can significantly hinder daily activities. These complications typically emerge within two to five years after diagnosis in 50% of patients, and in nearly all patients after 10 years.

Various pharmacologic strategies, device-assisted therapies, and surgical treatments are available to manage motor complications in advanced PD, especially when symptoms are not adequately controlled by medical

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

therapy. These interventions include deep brain stimulation (DBS), focused ultrasound therapy (FUS), continuous levodopa-carbidopa intestinal gel (LCIG) infusion, and continuous subcutaneous apomorphine infusion (CSAI).

On October 17, 2024, the U.S. Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa), the first 24-hour subcutaneous levodopa-based infusion therapy for managing motor fluctuations in adults with advanced Parkinson's disease (PD). The continuous delivery system ensures steady plasma levels of levodopa, leading to improved 'on' time without troublesome dyskinesia. The approval was supported by a pivotal 12-week, Phase 3 randomized, double-blind study comparing the efficacy of continuous subcutaneous Vyalev infusion to oral immediate-release carbidopa/levodopa (CD/LD IR), as well as data from a 52-week open-label trial evaluating the long-term safety and efficacy of Vyalev.

The Phase 3 trial enrolled approximately 130 adults with advanced PD across 80 sites in the U.S. and Australia. Patients were randomized to receive either continuous subcutaneous Vyalev plus oral placebo capsules or oral CD/LD IR capsules plus subcutaneous placebo. The primary endpoint was the change in "on" time without troublesome dyskinesia over 12 weeks, normalized to a 16-hour waking period. Vyalev demonstrated a significant increase in "on" time without troublesome dyskinesia (2.72 hours) compared to CD/LD IR (0.97 hours; p=0.0083), with improvements observed from the first week and maintained throughout the study. Most adverse reactions with Vyalev were non-serious and mild to moderate in severity, including infusion site events, hallucinations, and dyskinesia.

In the separate 52-week open-label study, 244 patients with levodopa-responsive PD and at least 2.5 hours of daily "off" time received 24-hour Vyalev infusion. The primary endpoint was safety and tolerability, with secondary endpoints assessing motor symptoms, quality of life, and functional outcomes. At week 52, "on" time without troublesome dyskinesia improved by 3.8 hours and "off" time decreased by 3.5 hours. The percentage of patients experiencing morning akinesia dropped from 77.7% at baseline to 27.8%. Improvements were also seen in sleep quality and quality of life measures. Most adverse events were mild or moderate, with infusion site reactions being the most common.

VYALEV (foscarbidopa and foslevodopa) is approved for subcutaneous administration only, preferably in the abdomen, using the VYAFUSER pump. According to the labeling information, patients prescribed VYALEV should be trained on the proper use of the delivery system and be able to operate it independently or with caregiver assistance.

Approved Indications

- A. VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).

Other Uses

- A. None

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Foscarbidopa and Foslevodopa (VYALEV) (This coverage criterion has been developed in accordance with LCD L33794 (External Infusion Pumps) and its associated Policy Article.)

A. Criteria For Initial Approval (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

- i. Individual has a diagnosis of advanced idiopathic Parkinson’s disease (PD) with motor fluctuations; **AND**
- ii. The individual meets one of the following:
 - A. Non-Infusion Therapy Optimization Failure:
 - 1. Documentation is provided that the individual’s condition is responsive to levodopa; **AND**
 - 2. The individual is using a minimum daily dose of 400 mg of oral levodopa (including combination products); **AND**
 - 3. The individual is using the following non-infusion-based Parkinson’s disease medications:
 - a. Oral levodopa-carbidopa; **AND**
 - b. A dopamine agonist; **AND**
 - c. One of the following:
 - i. A catechol-O-methyltransferase (COMT) inhibitor; **OR**
 - ii. An adenosine receptor antagonist (e.g., Nourianz); **AND**
 - 4. The dosage and/or dosing interval of non-infusion-based Parkinson’s disease therapies cannot be further optimized due to intolerance, dyskinesia, and/or other adverse effects; **AND**
 - 5. Despite optimal medical therapy, the individual continues to experience both:
 - a. Inadequate control of motor fluctuation symptoms affecting daily living (e.g., unpredictable stiffness, tremor, bradykinesia); **AND**
 - b. A minimum of 2.5 hours of “Off” time per day.

OR

B. Transition From Another Infusion-Based Therapy:

- 1. The individual is currently receiving an infusion-based Parkinson’s disease therapy (including enteral suspension) and is being transitioned to a different infusion-based therapy, such as VYALEV, due to clinical need.

AND

- iii. Individual meets all of the following criteria:

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

- A. The individual will not use VYALEV in combination with a monoamine oxidase (MAO) inhibitor (including, but not limited to, phenelzine or tranylcypromine); **AND**
- B. If the individual is currently using a MAO inhibitor (including, but not limited to, phenelzine or tranylcypromine), it will be discontinued, and VYALEV will be initiated at least 2 weeks after discontinuation;

AND

- iv. VYALEV will be administered subcutaneously via the VYAFUSER pump.

B. Criteria For Continuation of Therapy

- i. MMM considers continuation of Foscarbidopa and Foslevodopa (VYALEV) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when:
 - A. Documentation is provided confirming that there has been clinically significant improvement or stabilization in clinical signs and symptoms of disease.

C. Authorization Duration

- i. Initial Approval Duration: Up to 6 months
- ii. Reauthorization Approval Duration: Up to 6 months

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. Individual is receiving a nonselective MAO inhibitor (including but not limited to phenelzine or tranylcypromine); **OR**
- ii. Individual has a diagnosis of atypical PD or secondary PD; **OR**
- iii. When the above criteria are not met and for all other indications.

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Recommended Dosing Schedule
Foscarbidopa and Foslevodopa (VYALEV)	The maximum recommended daily dosage of VYALEV is 3,525 mg of foslevodopa (approximately 2,500 mg levodopa), which equates to approximately 30 vials per month when administered during 16 awake hours.
Exceptions	
None	

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
G20.B1	Parkinson's disease with dyskinesia, without mention of fluctuations
G20.B2	Parkinson's disease with dyskinesia and fluctuations
G20.A2	Parkinson's disease without dyskinesia, with fluctuations.
G20.A1	Parkinson's disease without dyskinesia, without mention of fluctuations

HCPCS Codes:

Codes	Description
J7356	Injection, Foscarbidopa 0.25 Mg/Foslevodopa 5 Mg
Pump and Ancillaries	
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient
A4222	Infusion supplies for external drug infusion pump; per cassette or bag
A9900	Miscellaneous DME supply, accessory, and/or service component of another HCPCS code
K0604	Replacement battery for external infusion pump owned by patient, lithium, 3.6 volt, each

CPT Codes:

Codes	Description
96369	Subcutaneous infusion for therapy or prophylaxis initial (\leq 1 hour)
96370	Subcutaneous infusion for therapy or prophylaxis ($>$ 1 hour)

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

Reference Information:

- Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD) L33794 – External Infusion Pumps, including coverage criteria related to infusion-based therapy for Parkinson’s Disease (effective for services performed on or after January 25, 2026). Available at the Medicare Coverage Database: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33794&ver=164&>.
- Soileau, M., et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. *Lancet Neurol.* 2022 Dec;21(12):P1099-1109.
- Aldred, J., et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. *Neurol Ther.* 2023 Dec;12(6):1937-1958.
- Ling, TW., et al. Medical Management Of Motor Fluctuations And Dyskinesia In Parkinson Disease. UpToDate. Last Updated Sept. 23, 2024.
- Spindler M., et al. Initial pharmacologic treatment of Parkinson disease. Last Updated July 15, 2024.
- Vyalev [package insert]. North Chicago, IL: AbbVie Inc.; October 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Utilization Management and Clinical Medical Policy

Policy Name: MP-RX-FP-164-24	Policy Number: MP-RX-FP-164-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 12/17/2024 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	--	--	--	---

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Select Review	Updated coverage criteria to align with CMS Local Coverage Determination (LCD) L33794 (External Infusion Pumps) by adding coverage pathways for infusion-based Parkinson’s disease therapy when non-infusion-based treatment cannot be further optimized or when transitioning from an existing infusion-based therapy. Coding Reviewed: Added ICD-10-CM G20.A1; added HCPCS J7356 (effective 7/1/2025), E0781 (VYAFUSER external infusion pump), K0552(cartridge), A9900 (vial adapter), K0604 (replacement battery), and A4222 (infusion supplies); deleted J7799, A4221, and E1399.	3/17/2026	03/24/2026
Annual Review	Remove MAO inhibitor as one of the required agents because of contraindications regarding drug class. Word formatting: Coding reviewed: No change.	10/7/2025	10/17/2025
Policy Inception	New Policy Creation	12/9/2024	12/17/2024
Choose an item.			